He will also serve as the chair of the audit committee of the board.
Lee has more than 40 years of experience in advising biotechnology companies in all aspects of a company's financial life cycle from strategic fundraising to initial public offering and mergers and acquisitions.
Kenneth Lee currently serves as a General Partner with Hatteras Venture Partners, a venture fund focused on healthcare and life sciences, which he joined in 2003, and where he is involved in deal sourcing, investment decisions and implementing exit strategies.
Previously, he was president of A.M. Pappas and Associates, LLC, a venture development firm, which he joined following 29 years with Ernst and Young. At Ernst and Young, Kenneth co-founded the firm's national life sciences practice.
Lee is a nationally-recognized financial matters expert and has served on eight public life sciences company boards, including Abgenix, CV Therapeutics, Maxygen and OSI Pharmaceuticals.
He previously served as chairman of the Inspire Pharmaceuticals board until the company's sale to Merck in 2011.
Ken currently serves on the boards of Aralez, Inc., Eyenovia and BioCryst Pharmaceuticals. He received his B.A. in Business Administration from Lenoir-Rhyne College and his MBA from the University of North Carolina at Chapel Hill.
Dance Biopharm is a private company based in the San Francisco Bay Area focused on developing novel inhaled formulations of biologics to treat diabetes and other serious chronic diseases.
The company began operations in 2010, and was founded by John Patton, Ph.D., who has over 25 years of experience developing numerous inhaled therapies including insulin.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults